2016
Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk
Lee A, Ness R, Roman L, Terry K, Schildkraut J, Chang-Claude J, Doherty J, Menon U, Cramer D, Gayther S, Risch H, Gentry-Maharaj A, Goodman M, Modugno F, Eilber U, Moysich K, Berchuck A, Rossing M, Jensen A, Wicklund K, Cushing-Haugen K, Hogdall E, Rudolph A, Thompson P, Wilkens L, Kjaer S, Carney M, Stram D, Ramus S, Wu A, Pike M, Pearce C. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstetrical & Gynecological Survey 2016, 71: 470-471. DOI: 10.1097/01.ogx.0000489579.62561.b8.Peer-Reviewed Original ResearchAssociation Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk
Lee AW, Ness RB, Roman LD, Terry KL, Schildkraut JM, Chang-Claude J, Doherty JA, Menon U, Cramer DW, Gayther SA, Risch H, Gentry-Maharaj A, Goodman MT, Modugno F, Eilber U, Moysich KB, Berchuck A, Rossing MA, Jensen A, Wicklund KG, Cushing-Haugen KL, Hogdall E, Rudolph A, Thompson PJ, Wilkens LR, Kjaer SK, Carney ME, Stram DO, Ramus SJ, Wu AH, Pike MC, Pearce CL. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstetrics And Gynecology 2016, 127: 828-836. PMID: 27054934, PMCID: PMC4892111, DOI: 10.1097/aog.0000000000001387.Peer-Reviewed Original ResearchConceptsEndometrioid ovarian carcinomaTherapy useOvarian carcinomaPostmenopausal estrogenControl groupPopulation-based case-control studyCase-control studyOvarian carcinoma histotypesOvarian carcinoma riskConditional logistic regressionOvarian Cancer Association ConsortiumSerous ovarian carcinomaDuration of useTiming of useTherapy usersMenopausal estrogensPooled analysisRisk factorsSelf-reported questionnaire dataCarcinoma riskCarcinomaEstrogenRecent usersLogistic regressionHistotype
2002
Histopathologic Features of Genetically Determined Ovarian Cancer
Shaw P, McLaughlin J, Zweemer R, Narod S, Risch H, Verheijen R, Ryan A, Menko F, Kenemans P, Jacobs I. Histopathologic Features of Genetically Determined Ovarian Cancer. International Journal Of Gynecological Pathology 2002, 21: 407-411. PMID: 12352190, DOI: 10.1097/00004347-200210000-00011.Peer-Reviewed Original ResearchConceptsInvasive serous carcinomasOvarian carcinomaSilverberg gradeGermline mutationsHistologic typeSerous carcinomaNuclear gradeGOG grade 3High histologic gradeBRCA1/BRCA2Serous histologyGynecologic pathologistsHistologic featuresHistopathologic featuresBRCA carriersHistologic gradeBRCA mutationsOvarian cancerArchitectural gradeBRCA2 mutationsGrade 3Germline BRCA1CarcinomaMutation statusControl group
1997
Perineal talc exposure and risk of ovarian carcinoma
Chang S, Risch H. Perineal talc exposure and risk of ovarian carcinoma. Cancer 1997, 79: 2396-2401. PMID: 9191529, DOI: 10.1002/(sici)1097-0142(19970615)79:12<2396::aid-cncr15>3.0.co;2-m.Peer-Reviewed Original ResearchConceptsOvarian carcinomaTalc exposureFrequency of exposureUnconditional logistic regression methodsTalcum powder useInvasive ovarian carcinomasBorderline significant associationPerineal talc exposureBorderline carcinomaMenstrual historyInvasive carcinomaCarcinoma typesEpidemiologic studiesEpidemiologic investigationsCarcinomaSignificant associationPowder useHistologic sectionsLogistic regression methodRole of talcSignificant riskFurther studiesOnly riskRiskPerineum
1996
Estrogen Replacement Therapy and Risk of Epithelial Ovarian Cancer
Risch H. Estrogen Replacement Therapy and Risk of Epithelial Ovarian Cancer. Gynecologic Oncology 1996, 63: 254-257. PMID: 8910636, DOI: 10.1006/gyno.1996.0315.Peer-Reviewed Original ResearchConceptsEstrogen replacement therapyEpithelial ovarian cancerOvarian cancerReplacement therapyRelative oddsInvasive epithelial ovarian cancerMultivariate logistic regression analysisHistology-specific analysisNonmucinous ovarian cancerOral contraceptive usageLogistic regression analysisERT usageERT useMucinous tumorsTumor histologyMenopausal womenSerous carcinomaEndometrioid carcinomaHistologic groupsNonmucinous typeCancerCarcinomaRegression analysisPopulation controlsTherapy